Mergers & AcquisitionsMedium•29 September 2026•
1 min read
Lundbeck Expresses Interest in Acquiring Xeris Biopharma
Key Facts
1Danish drugmaker Lundbeck has expressed interest in acquiring Chicago-based Xeris Biopharma, according to Bloomberg News.
Danish drugmaker Lundbeck has expressed interest in acquiring Chicago-based Xeris Biopharma, Reuters reported. The Danish pharmaceutical company is reportedly exploring the potential deal, citing information originally published by Bloomberg News.
XERS closed at $9.83 on September 28, 2026, having reached a day high of $10.01 and a low of $9 during that session. The interest is part of potential consolidation in the biopharma sector, though specific strategic motives or deal terms have not been disclosed.